Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients GlobeNewswire - Mon Apr 27, 6:30AM CDT

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations...

CRMD : 7.65 (+3.10%)
CorMedix to Participate in Needham Virtual Healthcare Conference GlobeNewswire - Tue Apr 7, 7:30AM CDT

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.65 (+3.10%)
CorMedix: Q4 Earnings Snapshot AP - Thu Mar 5, 6:56AM CST

CorMedix: Q4 Earnings Snapshot

CRMD : 7.65 (+3.10%)
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Mar 5, 6:30AM CST

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒    ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒...

CRMD : 7.65 (+3.10%)
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 GlobeNewswire - Mon Mar 2, 7:30AM CST

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.65 (+3.10%)
CorMedix to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Feb 12, 7:30AM CST

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.65 (+3.10%)
CorMedix Therapeutics Announces Share Repurchase Program GlobeNewswire - Mon Feb 2, 7:30AM CST

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.65 (+3.10%)
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 GlobeNewswire - Thu Jan 29, 7:30AM CST

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.65 (+3.10%)
MarketBeat.com
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 MarketBeat - Mon Jan 19, 10:28AM CST

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 24.91 (-1.85%)
ATAI : 4.41 (-4.75%)
CRMD : 7.65 (+3.10%)
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation Newsfile - Wed Jan 14, 9:12AM CST

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential...

CRMD : 7.65 (+3.10%)

Barchart Exclusives

Down Nearly 30% in 2026, is SoFi Stock a Buy Before the Q1 Earnings? Barchart - 9 minutes ago
SoFi's stock is down almost 30% in 2026. The stock, however, looks like a buy heading into the Q1 2026 earnings on tepid valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.